BiotechTube

E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acquired Immunodeficiency Syndrome

Conditions

Acquired Immunodeficiency Syndrome, HIV Infections

Trial Timeline

Dec 28, 2011 → Aug 22, 2016

NCT ID
NCT01497899

About E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF Placebo

E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF Placebo is a phase 2 stage product being developed by Gilead Sciences for Acquired Immunodeficiency Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01497899. Target conditions include Acquired Immunodeficiency Syndrome, HIV Infections.

What happened to similar drugs?

4 of 20 similar drugs in Acquired Immunodeficiency Syndrome were approved

Approved (4) Terminated (4) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅Zavicefta, Ceftazidime-AvibactamPfizerApproved
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
✅TelithromycinSanofiApproved
🔄IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
🔄PI + RTV + FTC/TDF + StribildGilead SciencesPhase 3
🔄E/C/F/TDF + COBI + ATV + DRV + NRTIGilead SciencesPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01497899Phase 2Completed

Competing Products

20 competing products in Acquired Immunodeficiency Syndrome

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2
35
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
42
Ticagrelor + PlaceboAstraZenecaPhase 2
27
IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
40
Raltegravir + AtazanavirMerckPre-clinical
26
Emicizumab InjectionRochePhase 2
35
PI + RTV + FTC/TDF + StribildGilead SciencesPhase 3
40
E/C/F/TDF + COBI + ATV + DRV + NRTIGilead SciencesPhase 3
40
COBI + DRV + NRTIsGilead SciencesPhase 3
40
StribildGilead SciencesPhase 3
40
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOSGilead SciencesPhase 2/3
42
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF PlaceboGilead SciencesPhase 2
35
Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
35
E/C/F/TAF + E/C/F/TAF (Low Dose)Gilead SciencesPhase 2/3
38
E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAFGilead SciencesPhase 3
40
NNRTI + FTC/TDF + StribildGilead SciencesPhase 3
40
EVG + Background regimenGilead SciencesPhase 2/3
30
EVG/COBI/FTC/TDFGilead SciencesPhase 2/3
38